Articles from Truveta

BELLEVUE, Wash., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Truveta is proud to announce the publication of its latest peer-reviewed research in Radiology Advances: “XComposition: Multimodal Deep Learning Model to Measure Body Composition Using Chest Radiographs and Clinical Data.” This groundbreaking study demonstrates the power of artificial intelligence to estimate critical body composition measures—such as visceral and subcutaneous fat volumes—from a simple chest radiograph combined with commonly available clinical data. The deep learning model is available as a Python library for others to experiment with in Truveta’s GitHub.

Unique device identifier data linked with ADT and chargemaster data give medical device manufacturers unmatched visibility into device use, safety, and outcomes—accelerating regulatory submissions, discovering safety signals faster, and speeding innovation that shapes guidelines and standards of care.

BELLEVUE, Wash., July 14, 2025 (GLOBE NEWSWIRE) -- A groundbreaking study published today in Pediatrics Open Science shows a notable increase in the use of medication to treat pediatric obesity in the United States following the 2023 release of comprehensive guidelines by the American Academy of Pediatrics (AAP). The study, conducted by researchers from Truveta and Davene R. Wright, PhD of Harvard Medical School, analyzed real-world electronic health records from Truveta from more than 300,000 children and adolescents and provides the first large-scale evidence of how clinical practice has shifted since the guidelines were introduced.

BELLEVUE, Wash., May 08, 2025 (GLOBE NEWSWIRE) -- Today, Truveta announced a new era in cancer research with more than 7 million oncology patient journeys spanning more than 100 cancer types, delivering an unprecedented breadth of regulatory grade data to support researchers in accelerating oncology therapy adoption and advancing critical cancer research.

Published in the American Journal of Preventative Medicine, the new study shows that for the first time since its peak in 2022, syphilis incidence has declined, with larger decreases for men and young adults.

BELLEVUE, Wash., March 26, 2025 (GLOBE NEWSWIRE) -- Today, Truveta announced that Truveta Data has expanded to include new administrative data to enable more comprehensive analyses of healthcare outcomes and patient journeys. The company also announced two new Truveta Studio capabilities: the ability to create feature tables in minutes and eligibility filters, which accelerate regulatory grade research with immediate access to Truveta Data and powerful analytics.

Closed claims complete the longitudinal patient journey in Truveta Data, enabling regulatory grade safety and effectiveness studies, replacing clinical trials and registries

New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine and The Wharton School at University of Pennsylvania

The Regeneron Genetics Center® will sequence up to ten million exomes, helping to accelerate drug discovery and transform patient care

HITRUST r2 Certification demonstrates Truveta’s relentless commitment to the highest standards of security and privacy to protect regulatory-grade data.

Researchers with more than 100 organizations use regulatory-grade Truveta Data to enable their scientifically rigorous research

Trained on the Truveta Language Model and Truveta Data, the most complete and representative EHR data, Tru enables researchers to accelerate their research in Truveta Studio using simple, natural language

Truveta will enable The CHOICE Institute with complete, timely, and clean real-world data to improve patient care and advance medicine

In the largest comparative effectiveness study of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss using real-world data – now published in JAMA Internal Medicine – Truveta Research found that patients with overweight or obesity taking tirzepatide were three times more likely to achieve 15% weight loss than those taking semaglutide.

With industry-leading certifications and rigorous third-party audits, Truveta announces new capabilities to enable successful regulatory submissions and audits.

BELLEVUE, Wash., May 13, 2024 (GLOBE NEWSWIRE) -- Today Truveta, a growing collective of more than 30 health systems with a mission of Saving Lives with Data, welcomes Rod Hochman, MD, president and CEO of Providence, as its new Board of Directors Chair. Truveta’s Board of Directors ensures Truveta is operating in pursuit of its mission, providing strategic, scientific, and operational direction.

From detailed family history and complex concepts from a wide range of therapeutic areas to millions of de-identified medical images, Truveta empowers researchers with the most complete, timely, and clean data.

BELLEVUE, Wash., April 25, 2024 (GLOBE NEWSWIRE) -- Truveta, the company with a mission of Saving Lives with Data, announced today the largest and most complete mother-child electronic health record (EHR) dataset for scientifically rigorous research on mothers and their children. Truveta empowers researchers with unparalleled insights into the continuum of care from pre-pregnancy through childbirth and beyond, while upholding the highest standards of privacy protection and regulatory compliance.

BELLEVUE, Wash., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Today, Truveta, a growing collective of 30 health systems with a shared mission of Saving Lives with Data, was awarded a contract with the U.S. Centers for Disease Control and Prevention (CDC) for privacy-preserving record linkage of patient-level real-world healthcare data. Truveta will provide real-world data for CDC researchers to conduct respiratory virus surveillance, including COVID-19, as well as data to facilitate studies on maternal health and pediatric care.  

In a study of more than 2.4 million children under the age of 5, new research shows a significant increase in the rate of first-time speech delay diagnoses after July 2020.

BELLEVUE, Wash., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Truveta, the company with a mission of saving lives with data, welcomes its first member from the life science industry to its Board of Directors. The Truveta Board of Directors ensures the data and analytics company is operating in pursuit of its mission, providing strategic, scientific, and operational direction.

In the first comparative effectiveness study of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss using real-world data, Truveta Research found that patients with overweight or obesity taking tirzepatide were three times more likely to achieve 15% weight loss than those taking semaglutide (Ozempic).

With more than 56.6 million clinical observations from more than 2.7 million echocardiogram reports and growing, Truveta is the market leader in real-world data for cardiovascular research.

Bellevue, WASH., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Truveta announced today that it is partnering with more than 50 organizations in life sciences, healthcare, government, academic medical centers, and research institutes to study safety and effectiveness, improve patient care and train medical AI. Truveta welcomes researchers from Boehringer Ingelheim, Moderna, UCB, and others studying various diseases, drugs, and devices with Truveta’s data and analytics solutions. These new organizations join existing innovators like Pfizer, Boston Scientific, Alpine Immune Sciences, Reprieve Cardiovascular, SK Life Sciences, MedComp, Mathematica, and more. In addition to life sciences companies, Truveta also announced that Duke University will access existing Truveta Data to advance research broadly across many conditions.

Truveta has completed its Type 2 SOC 2 examination and continue to maintain ISO 27001 certifications, demonstrating the company’s relentless commitment to security, privacy, and trust.

Powerful partnership will allow researchers access to the most complete, timely, and clean health data to improve outcomes

Truveta Data will enable Medical Components, Inc. to study manufacturer-specific medical device data to address medical evidence gaps and improve clinical care recommendations.

With new medication dispense data – including prescription fill data from specialty pharmacies – Truveta Data offers even more complete, timely, and clean data to study patient care and outcomes.

BELLEVUE, Wash., May 17, 2023 (GLOBE NEWSWIRE) -- Today Truveta, a leader in electronic health record (EHR) data and analytics, announces the expansion of its community to include new life science partners, including Reprieve Cardiovascular and SK Life Science, joining previously announced pioneers Pfizer, Boston Scientific Corporation, and Alpine Immune Sciences. Truveta also welcomes new health system members, including Inova Health System and Sanford Health.

New research published in JAMA Network Open shows changes in minoxidil prescribing following media attention about oral use for hair loss.

Truveta’s clinical expert-led AI delivers the cleanest healthcare data, including structured concepts from clinician notes

Truveta’s 28 health system members provide over 16% of patient care in the United States.

Expanded de-identified social drivers of health data in Truveta Studio empower new health equity scenarios to study health disparities and improve patient care.

In a study of more than 1.2 million patients, new research shows the interaction effects of multiple comorbidities on the increased risk of COVID-19 breakthrough infections and hospitalizations.

Among women with preeclampsia, new Truveta Research findings show that Black women are two times more likely to experience heart failure than white women.

With 27 health system members, Truveta now includes de-identified patient journeys from all 50 US states.

New Truveta Research monitoring report shows rates of RSV hospitalizations compared to previous years, part of new research capabilities in Truveta Studio for ongoing disease monitoring.

New research published in Frontiers in Public Health shows racial disparities in COVID-19 hospitalization lengths of stay and access to treatments early in the pandemic.

First data and analytics solution to study patient care and outcomes now available